The drug, called Arixvi, is approved for use by people age 60 or older to prevent RSV.
What is “respiratory syncytial virus”?
• A virus that causes infections in the lungs and respiratory tract.
• It is so common that most children have it before the age of two.
• The virus can also infect adults.
• For healthy older people and children, symptoms of the virus are mild, usually similar to those of a cold.
• Self-care measures are usually all that is needed to alleviate the feeling of illness.
virus severity
But the director of the US Food and Drug Administration’s Center for Biology, Peter Marks, said: “Older people, especially those with particular health conditions such as heart or lung disease or an immune system weakened, are at increased risk of severe illness from RSV.”
“The approval of the first RSV vaccine is a significant public health achievement for the prevention of a life-threatening disease and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in states. -United.
Benefits of the vaccine
And the United States Food and Drug Administration has conducted an ongoing, randomized, placebo-controlled clinical study to ensure the safety and efficacy of a single-dose “Arixvi” for people 60 years of age or older, according to the information network “Fox News”.
Of the 25,000 study participants, half received the vaccine and the other half received a placebo.
The U.S. Food and Drug Administration said the vaccine significantly reduced the risk of developing RSV-related illnesses by 82.6 to 94.1 percent.
Read the Latest World News Today on The Eastern Herald.
